
Rosalyn Jane Hithersay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2245609/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transfer of Cognitive Training across Magnitude Dimensions Achieved with Concurrent Brain Stimulation of the Parietal Lobe. Journal of Neuroscience, 2013, 33, 14899-14907.	3.6	196
2	Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMA Neurology, 2019, 76, 152.	9.0	110
3	Health comorbidities and cognitive abilities across the lifespan in Down syndrome. Journal of Neurodevelopmental Disorders, 2020, 12, 4.	3.1	85
4	Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's and Dementia, 2019, 15, 245-257.	0.8	68
5	Aging related cognitive changes associated with Alzheimer's disease in Down syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 741-751.	3.7	64
6	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	7.9	63
7	Assessment of an incentivised scheme to provide annual health checks in primary care for adults with intellectual disability: a longitudinal cohort study. Lancet Psychiatry,the, 2014, 1, 522-530.	7.4	58
8	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 26.	6.2	56
9	The LonDownS adult cognitive assessment to study cognitive abilities and decline in Down syndrome. Wellcome Open Research, 2016, 1, 11.	1.8	55
10	Cognitive decline and dementia in Down syndrome. Current Opinion in Psychiatry, 2017, 30, 102-107.	6.3	54
11	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurology, The, 2021, 20, 605-614.	10.2	29
12	Carer-led health interventions to monitor, promote and improve the health of adults with intellectual disabilities in the community: A systematic review. Research in Developmental Disabilities, 2014, 35, 887-907.	2.2	26
13	Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome. Frontiers in Psychiatry, 2019, 10, 158.	2.6	18
14	Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome. Alzheimer's and Dementia, 2021, 17, 595-604.	0.8	16
15	The Association between Physical Activity and CAMDEX-DS Changes Prior to the Onset of Alzheimer's Disease in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 1882.	2.4	14
16	Differential Associations of Apolipoprotein E ε4 Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome. JAMA Network Open, 2020, 3, e2018221.	5.9	7
17	[P3–328]: USING FUNCTIONAL NEAR INFRARED SPECTROSCOPY (FNIRS) TO MEASURE FRONTAL CORTICAL ACTIVITY IN ADULTS WITH DOWN SYNDROME. Alzheimer's and Dementia, 2017, 13, P1076.	0.8	0
18	O1â€08â€02: SEQUENCE OF COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME DURING PROGRESSION FROM PRECLINICAL TO PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P235.	0.8	0

#	Article	IF	CITATIONS
19	Reply to "Down Syndrome Cognitive Marker's Significance in Alzheimer's Disease and Dementia Management― Alzheimer's and Dementia, 2019, 15, 1238-1239.	0.8	0